Anticoagulation During Extracorporeal Membrane Oxygenation; Nafamostat Mesilate Versus Heparin

Nafamostat mesilate was found to increase the bleeding risk in patients receiving venoarterial ECMO. Regarding thromboembolic complications, there was no significant difference between heparin and nafamostat. Only old age increased the thromboembolic risk.